Two vaccines being tested in the UK have moved on to the third phase of trials, marking a significant step in the production. Novavax has started its Phase 3 trial of an experimental COVID-19 vaccine in the UK. The US biotechnology firm is to enrol 10,000 people out of 250,000 volunteers aged between 18 and 84 over the next four to six weeks. The company joins AstraZeneca, Pfizer, and Moderna as its coronavirus vaccine candidate enters the final step of the regulatory approvals process.
Coronavirus: New Norovax vaccine trial set to begin in UK
